Senses Disorder TRIZ Cases

Indazole compounds inhibit Wnt signaling and DYRK1A enzyme activity to address the lack of effective dual inhibitors for cancer and neurodegenerative disorders.

Selective GPR43 agonists reduce TNF-α and IL-8 levels to alleviate rheumatoid arthritis symptoms without broad immunosuppression.

Benzothiazole cyclobutyl amine derivatives act as histamine-3 receptor ligands.

Recombinant veterinary decorin compositions inhibit scar formation through specific amino acid mutations.

Attaching acidic peptides to enzyme N-terminus improves bone targeting and stability for Morquio disease treatment.

A polyamide compound with controlled hydrophilicity targets peripheral kappa-opioid receptors to provide effective pain relief.

A tacrolimus microemulsion composition delivers the drug across the skin barrier without occlusive dressings.

Codon-optimized PROM1 nucleotide sequence boosts expression levels threefold to treat retinitis pigmentosa.

Chimeric ActRII receptor inhibitors block myostatin signaling to preserve skeletal muscle mass in cancer patients.

Small molecule compounds modify cellular signaling pathways to promote regeneration of terminally differentiated sensory hair cells in the mammalian inner ear.

New GPR119 agonist compounds activate receptors to stimulate insulin secretion and improve beta cell function.

Short peptides inhibit insulin-degrading enzyme activity to preserve endogenous insulin levels.

Differentiation induction medium containing GSK3 inhibitors and retinoic acid drives stem cell conversion to functional corneal endothelial cells.

Covalent linking of riboside units via lipophilic groups increases intracellular NAD+ levels in damaged cells while avoiding broad dehydrogenase inhibition.

Topical lipid compositions enhance aqueous outflow through the trabecular meshwork, addressing limited efficacy of existing glaucoma treatments.

Low dose interleukin-2 selectively stimulates regulatory T lymphocytes, resolving the contradiction between expanding Tregs and activating effector cells.

Amide compounds inhibit cellular necrosis by targeting RIP1 kinase activity.

Latent transforming growth factor beta activates locally at inflammation sites to suppress autoreactive immunity without systemic toxicity.

Co-expressed MINION and Myomaker proteins fuse non-muscle cells, enabling efficient therapeutic agent delivery via liposomes.

Segmentation of the immune pathway via selective bicyclic kinase inhibition reduces immunosuppressive side effects.

Covalent oligomer conjugation modifies cannabinoid solubility to reduce blood-brain barrier penetration.

Modifying chemical structures of indoleamine-2,3-dioxygenase inhibitors reduces toxicity and stability issues while maintaining anti-tumor efficacy.

Dual benzazepine inhibitors target NEP and ECE-1 pathways to reduce intraocular pressure while preventing retinal ganglion cell apoptosis in glaucoma treatment.

Selective quinoline derivatives target the EP4 receptor to provide analgesic effects without gastrointestinal toxicity or renal side effects.

Substituted naphthyridines inhibit Syk kinase activity, addressing the lack of effective inhibitors for asthma and rheumatoid arthritis.

Novel antihypertensive polyol compounds alleviate vascular remodeling and right heart hypertrophy, reversing disease progression where existing therapies fail.

Formula I compounds inhibit Bruton's tyrosine kinase activity with high specificity, avoiding Src-family kinase inhibition and severe adverse effects.

A surfactant system stabilizes ophthalmic emulsions with small particle sizes while minimizing free hydrophilic surfactants that cause eye irritation.

Bicyclic pyrimidine compounds inhibit VEGFR and tubulin to overcome multidrug resistance.

Segmented H3N2 vaccine compositions target novel canine influenza strains to prevent severe respiratory disease in dogs.

Esterified hyaluronic acid absorbs blue light to protect retinal tissue, replacing bulky physical barriers with a chemical eye drop solution.

Modular N-heteroaryl indole carboxamides optimize TRPV1 binding affinity to reduce activity variability and improve therapeutic specificity.

Peptides modulate cytokine secretion to treat noise-induced and age-related hearing loss.

A Montelukast preparation process using alkaline metal cyanides and Grignard reagents to achieve high chemical and optical purity.

Oral compounds stimulate endogenous mesenchymal stem cell proliferation, bypassing lung trapping from intravenous injection.

DGAT1 inhibitors reduce postprandial triglycerides to treat familial chylomicronemia syndrome where fibrates fail.

A 2-pyridyl substituted imidazole derivative selectively inhibits ALK5 and ALK4 receptors.

Novel pyrimidone derivatives act as specific inhibitors of the GSK3β kinase enzyme.

Low-dose SGLT2 inhibitor agent ameliorates retinal function abnormalities by inhibiting sodium/glucose cotransporter 2 in retinal cells.

Segmented PKC inhibitors target specific isozymes to resolve the trade-off between broad disease coverage and precise therapeutic effectiveness.

Tricyclic quinoline derivatives selectively modulate the 5-HT2C receptor to treat schizophrenia while minimizing side effects from non-selective pharmacology.

A recombinant adeno-associated virus vector delivers transgenes to inner and outer hair cells.

Optimized excipient ratios enable high canagliflozin loading in tablets, reducing size while maintaining manufacturability.

Nanoscale pores in bioerodible silicon carriers enable sustained protein delivery while eliminating surgical removal trauma.

A viscous liquid depot forms a thin film on the eye to sustain pharmaceutical release.

Genetic screening of PRDM13 mutations guides stem cell selection to repair the macula while avoiding treatment complexity.

PEG-CNP prodrugs extend half-life and reduce cardiovascular side effects by enabling stable subcutaneous delivery.

A ring-shaped ocular device features a curved intermediate thickness to provide stable wear on the scleral surface.

A sterile ophthalmic composition using castor oil and medium chain triglycerides to promote mucin expression.